Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 92.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 243,795 shares of the biopharmaceutical company’s stock after purchasing an additional 116,832 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 0.37% of Celldex Therapeutics worth $8,287,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 16.3% during the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock worth $120,817,000 after buying an additional 427,827 shares during the period. Novo Holdings A S lifted its holdings in shares of Celldex Therapeutics by 13.4% during the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after acquiring an additional 113,663 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after acquiring an additional 2,664,915 shares during the last quarter. Swiss National Bank grew its holdings in Celldex Therapeutics by 17.8% in the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock valued at $4,797,000 after purchasing an additional 17,300 shares during the period. Finally, Jennison Associates LLC raised its stake in Celldex Therapeutics by 3,327.0% during the first quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after purchasing an additional 668,002 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CLDX. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday, October 28th. Citigroup assumed coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Down 1.5 %

NASDAQ CLDX opened at $25.68 on Friday. The stock has a market cap of $1.70 billion, a PE ratio of -9.37 and a beta of 1.60. The business has a 50 day moving average price of $34.89 and a two-hundred day moving average price of $36.23. Celldex Therapeutics, Inc. has a fifty-two week low of $23.72 and a fifty-two week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The business had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.